Brief: Poxel Reports H1 Financial Loss Of 1.2 Million Euros

Poxel SA

23/09/2021 17:12

Sept 23 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL REPORTS FINANCIAL RESULTS FOR FIRST HALF 2021 AND
PROVIDES
A CORPORATE UPDATE
    * STRENGTHENED FINANCIAL POSITION WITH APPROVAL OF TWYMEEG®
(IMEGLIMIN HYDROCHLORIDE) FOR TREATMENT OF TYPE 2 DIABETES IN
JAPAN
    * INCREASING STRATEGIC FOCUS ON RARE METABOLIC DISEASES WITH
CONTINUED COMMITMENT TO NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    * POXEL REPORTED REVENUES OF EUR 13.3 MILLION FOR SIX MONTHS
ENDED
JUNE 30, 2021, AS COMPARED TO EUR 6.4 MILLION DURING
CORRESPONDING PERIOD IN 2020
    * FINANCIAL LOSS AMOUNTED TO EUR 1.2 MILLION FOR FIRST HALF
OF
2021, AS COMPARED TO AN INCOME OF EUR 0.2 MILLION FOR FIRST HALF
OF 2020
    * AS OF JUNE 30, 2021, CASH AND CASH EQUIVALENTS WERE EUR
36.9
MILLION (USD 43.9 MILLION)

Source text for Eikon:  ID:nBw1YcJ31a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))